112 related articles for article (PubMed ID: 6150468)
1. Pro-Leu-Gly-NH2 and pareptide inhibit development of tolerance to haloperidol catalepsy in the mouse.
Mycroft FJ; Wei ET
Peptides; 1984; 5(5):883-7. PubMed ID: 6150468
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological activities of the MIF-1 analogues Pro-Leu-Gly, Tyr-Pro-Leu-Gly and pareptide.
Mycroft FJ; Bhargava HN; Wei ET
Peptides; 1987; 8(6):1051-5. PubMed ID: 2894644
[TBL] [Abstract][Full Text] [Related]
3. Acute administration of MIF-1 or Tyr-MIF-1 inhibits haloperidol-induced catalepsy in rats.
Hara C; Kastin AJ
Pharmacol Biochem Behav; 1986 Jun; 24(6):1785-7. PubMed ID: 2874569
[TBL] [Abstract][Full Text] [Related]
4. Tyr-MIF-1 attenuates development of tolerance to spiperone-induced catalepsy in rats.
Kostrzewa RM; Kastin AJ
Brain Res Bull; 1993; 31(6):707-12. PubMed ID: 8100182
[TBL] [Abstract][Full Text] [Related]
5. Structure activity relationship studies with hypothalamic peptide hormones. I. Effect of melanotropin release inhibiting factor and analogs on tolerance to morphine in the rat.
Bhargava HN; Kim HS
J Pharmacol Exp Ther; 1982 Feb; 220(2):394-8. PubMed ID: 6120229
[TBL] [Abstract][Full Text] [Related]
6. Structure activity relationship studies with hypothalamic peptide hormones III. Effect of melanotropin-release inhibiting factor and analogs on tolerance to morphine in the rat.
Bhargava HN; Kim HS
Neuropharmacology; 1982 Sep; 21(9):917-22. PubMed ID: 6128692
[TBL] [Abstract][Full Text] [Related]
7. Development of tolerance and reverse tolerance to haloperidol- and SCH23390-induced cataleptic effects during withdrawal periods after long-term treatment.
Ushijima I; Mizuki Y; Yamada M
Pharmacol Biochem Behav; 1995 Feb; 50(2):259-64. PubMed ID: 7740066
[TBL] [Abstract][Full Text] [Related]
8. The effects of a hypothalamic peptide factor, MIF and its cyclic analog on tolerance to haloperidol in the rat.
Bhargava HN
Life Sci; 1981 Jul; 29(1):45-51. PubMed ID: 6115301
[No Abstract] [Full Text] [Related]
9. Tripeptide analogues of melanocyte-stimulating hormone release-inhibiting hormone (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.
Björkman S; Castensson S; Sievertsson H
J Med Chem; 1979 Aug; 22(8):931-5. PubMed ID: 40028
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tolerance to the pharmacological effects of human beta-endorphin by prolyl-leucyl-glycinamide and cyclo(leucylglycine) in the rat.
Bhargava HN
J Pharmacol Exp Ther; 1981 Aug; 218(2):404-8. PubMed ID: 6114170
[TBL] [Abstract][Full Text] [Related]
11. MSH and MIF-I in animal models of tardive dyskinesia.
Davis KL; Kastin AJ; Beilstein BA; Vento AL
Pharmacol Biochem Behav; 1980 Jul; 13(1):37-40. PubMed ID: 6105677
[TBL] [Abstract][Full Text] [Related]
12. Alteration of cataleptic responses induced by dopamine receptor antagonists after chronic cocaine administration in mice.
Ushijima I; Mizuki Y; Yamada M
Eur J Pharmacol; 1995 Oct; 285(1):55-9. PubMed ID: 8846811
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of Pro-Leu-Gly-NH2 and cyclo(Leu-Gly) administered orally on the development of tolerance to the analgesic effect of morphine in the rat.
Bhargava HN; Ramarao P
Peptides; 1989; 10(4):767-71. PubMed ID: 2573893
[TBL] [Abstract][Full Text] [Related]
14. Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.
Voith K
Arzneimittelforschung; 1977; 27(12):2290-3. PubMed ID: 23795
[TBL] [Abstract][Full Text] [Related]
15. MIF (Pro-Leu-Gly-NH2): failure to affect oxotremorine effects in mice and rats as well as fluphenazine catalepsy or amphetamine hyperactivity in rats.
Björkman S; Lewander T; Zetterström T
J Pharm Pharmacol; 1980 Apr; 32(4):296-7. PubMed ID: 6103063
[No Abstract] [Full Text] [Related]
16. On the optimal dosage of Pro-Leu-Gly-NH2 (MIF) in neuropharmacological tests and clinical use.
Björkman S; Sievertsson H
Naunyn Schmiedebergs Arch Pharmacol; 1977 Jun; 298(2):79-81. PubMed ID: 18686
[TBL] [Abstract][Full Text] [Related]
17. Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration.
Lappalainen J; Hietala J; Syvälahti E
Psychopharmacology (Berl); 1989; 98(4):472-5. PubMed ID: 2570432
[TBL] [Abstract][Full Text] [Related]
18. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
Zharkovskiĭ AM; Matvienko OA; Nurk AM
Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
[TBL] [Abstract][Full Text] [Related]
19. Effects of chronic methamphetamine on SCH23390- or haloperidol-induced catalepsy, and effects of coadministration of SCH23390 or haloperidol in mice.
Mizuki Y; Ushijima I; Yamada M
Pharmacol Biochem Behav; 1996 Feb; 53(2):437-40. PubMed ID: 8808155
[TBL] [Abstract][Full Text] [Related]
20. Tolerance of haloperidol catalepsy.
Ezrin-Waters C; Seeman P
Eur J Pharmacol; 1977 Feb; 41(3):321-7. PubMed ID: 556989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
